Litifilimab-matching placebo

Phase 3

Litifilimab-matching placebo is one of 4 therapeutic programs targeting Systemic Lupus Erythematosus (SLE). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Systemic Lupus Erythematosus (SLE)Enrolling by invitation

Systemic Lupus Erythematosus (SLE)Phase 3

Enrolling by invitation

Competition

Competitive Landscape

9 competitors in Systemic Lupus Erythematosus (SLE)

#DrugCompanyPhaseTrials

Litifilimab

Biogen

Phase 3

1 2

Enpatoran

Merck & Co.

Phase 3

1 3

Litifilimab-matching placebo

Biogen

Phase 3

1 4

Universal Anti-CD70 CAR-T (CHT101)

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)1 trial

A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus

Enrolling by invitation· Biogen logo

Biogen·Phase 3·NCT05352919·864 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Litifilimab-matching placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Litifilimab-matching placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Biogen

Litifilimab-matching placebo

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)1 trial

References

Drug Info

Quick Facts

Related News